GlassScriptPhysician profile
Rajesh Chawla
NPI 1982657763
$8,912.33
in general payments reported to CMS, 2019-2025
30 companies · $1,057 in 2025
The $1,057 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,330 · 2020: $1,234 · 2021: $1,385 · 2022: $1,272 · 2023: $1,390 · 2024: $1,245 · 2025: $1,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,481 · Consulting Fee: $200 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.67 |
| Consulting Fee | $200.00 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,213.33 | 2021-2025 | Micra, Corevalve Evolut R, Selectsecure |
| Bayer Healthcare Pharmaceuticals INC. | $739.65 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $588.62 | 2023-2025 | Winrevair, Verquvo |
| Novartis Pharmaceuticals Corporation | $583.18 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $570.97 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Cardiovascular Systems INC. | $557.40 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $510.37 | 2019-2025 | Farxiga |
| Esperion Therapeutics, INC. | $482.20 | 2020-2023 | Nexletol |
| Amgen INC. | $451.20 | 2019-2025 | Krystexxa, Repatha |
| Boston Scientific Corporation | $409.36 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Bodyguardian, Accolade Sr |
| Abbott Laboratories | $356.81 | 2019-2025 | Jot Dx, Diamondback Peripheral, Starclose Se |
| Janssen Pharmaceuticals, INC | $308.16 | 2019-2023 | Xarelto |
| Medtronic Vascular, INC. | $302.64 | 2019-2020 | |
| United Therapeutics Corporation | $299.18 | 2019-2025 | Tyvaso, Orenitram |
| Sanofi-Aventis U.S. LLC | $285.55 | 2019-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $248.19 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $245.76 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.57 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $119.46 | 2020-2021 | |
| Lexicon Pharmaceuticals, INC. | $102.24 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.77 | 2019-2024 | Lifevest |
| Shockwave Medical, INC | $42.67 | 2025 | |
| Lilly USA, LLC | $36.57 | 2021 | |
| Lundbeck LLC | $36.08 | 2020 | |
| Arbor Pharmaceuticals, INC. | $35.92 | 2020-2022 | |
| Gilead Sciences, INC. | $32.41 | 2019 | |
| Novo Nordisk INC | $20.00 | 2024 | Rybelsus, Ozempic |
| Kowa Pharmaceuticals America, INC. | $17.51 | 2023 | Livalo |
| Cardinal Health 200 LLC | $17.25 | 2020 | |
| Celgene Corporation | $15.31 | 2024 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajesh Chawla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.